Kairos Pharma, Ltd. (KAPA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Kairos Pharma, Ltd., a Delaware corporation, on February 26, 2026. The Company is an emerging growth company with its principal executive offices in Los Angeles, California. The report discloses a material event under Item 8.01 regarding a strategic acquisition initiative.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate transaction and does not include financial statement data.
Material Changes and Events
On February 26, 2026, the Company entered into a letter of intent with Celyn Therapeutics, Inc., a privately held biotechnology company. The agreement grants Kairos Pharma the right to acquire worldwide rights to two clinical-stage oncology assets targeting non-small cell lung cancers (NSCLC):
- CL-273: A pre-IND, reversible, wild-type-sparing pan-EGFR inhibitor.
- CL-741: A Phase 1-ready, orally available type IIb c-MET kinase inhibitor.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance or management commentary on future performance. The transaction is based on a letter of intent and term sheet, implying that the acquisition is not yet finalized. The press release associated with this event is furnished as Exhibit 99.1 and is not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting the legal liability of the statements within.
Investor Verification Checklist
- Verify the final terms of the acquisition agreement with Celyn Therapeutics, Inc., as the current status is a letter of intent.
- Confirm the regulatory status and development timelines for assets CL-273 and CL-741.
- Review the Company's cash position and capitalization to assess its ability to fund the proposed acquisition.
- Monitor for a definitive agreement or termination of the letter of intent in future filings.